Zydus Cadila becomes second Indian pharma with US IND for GK activator in diabetes
This article was originally published in Scrip
Executive Summary
Zydus Cadila, one of India’s leading healthcare companies announced that it has received an IND approval from the US FDA for ZYGK1, an orally administered small molecule glucokinase activator for Type 2 diabetes. The move reinforces Zydus' transition from its heavy dependence on generics to its ambitions as a research-led company. It also makes Zydus the second Indian company exploring the glucokinase activation space, alongside Advinus.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.